Please use this identifier to cite or link to this item: doi:10.22028/D291-37762
Volltext verfügbar? / Dokumentlieferung
Title: Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study
Author(s): Erlmeier, Franziska
Steffens, Sandra
Stöhr, Christine
Herrmann, Edwin
Polifka, Iris
Agaimy, Abbas
Trojan, Lutz
Ströbel, Philipp
Becker, Frank
Wülfing, Christian
Barth, Peter
Stöckle, Michael
Staehler, Michael
Stief, Christian
Haferkamp, Axel
Hohenfellner, Markus
Macher-Göppinger, Stephan
Wullich, Bernd
Noldus, Joachim
Brenner, Walburgis
Roos, Frederik C.
Walter, Bernhard
Otto, Wolfgang
Burger, Maximilian
Schrader, Andres Jan
Hartmann, Arndt
Ivanyi, Philipp
Language: English
Title: Clinical Genitourinary Cancer
Volume: 19 (2021)
Issue: 1
Pages: 53-59.e1
Publisher/Platform: Elsevier
Year of Publication: 2020
DDC notations: 610 Medicine and health
Publikation type: Journal Article
Abstract: Background Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) play a decisive role as prognostic markers in clear-cell renal cell carcinoma (RCC). To date, the role of PD-1/PD-L1 as a prognostic marker in papillary RCC (pRCC) remains scarce. Patients and Methods Patients’ sample collection was a joint collaboration of the nationwide PANZAR consortium – a multicenter study. Medical history and tumor specimens were collected from 245 and 129 patients with pRCC types 1 and 2, respectively. Expression of PD-1 and PD-L1 was determined by immunohistochemistry in pRCC and tumor-infiltrating mononuclear cells. Results Of 374 pRCC specimens, 204 type 1 and 97 type 2 were evaluable for PD-1 and PD-L1 expression analysis. In total, PD-1 and PD-L1 expression were found in 8 (4.9%) of 162 and 12 (7.2%) of 166 evaluable pRCC type 1 specimens. Comparably, PD-1 and PD-L1 expression were found in 2 (2.4%) of 83 and 5 (6.2%) of 81 evaluable pRCC type 2 specimens. Hardly any clinically relevant associations between PD-1 and PD-L1 positivity and clinicopathologic or clinical courses were observed, neither in pRCC type 1 nor type 2. Conclusion The analysis of a large pRCC cohort from a multicenter consortium revealed no impact of PD-1/PD-L1 expression on prognosis in patients with pRCC with predominantly limited disease status, neither for type 1 nor type 2. However, the impact of PD-1 and PD-L1 in more advanced pRCC disease needs further elucidation.
DOI of the first publication: 10.1016/j.clgc.2020.07.002
URL of the first publication:
Link to this record: urn:nbn:de:bsz:291--ds-377624
ISSN: 1558-7673
Date of registration: 28-Oct-2022
Faculty: M - Medizinische Fakultät
Department: M - Urologie und Kinderurologie
Professorship: M - Prof. Dr. Michael Stöckle
Collections:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Files for this record:
There are no files associated with this item.

Items in SciDok are protected by copyright, with all rights reserved, unless otherwise indicated.